Using a groundbreaking gene editing technique, University of California scientists have created a strain of mosquitoes capable of rapidly introducing malaria-blocking genes into a mosquito population through its progeny, ultimately eliminating the insects' ability to transmit the disease to humans.
The study underlines the growing utility of the Crisper method, a powerful gene editing tool that allows access to a cell's nucleus to snip DNA to either replace mutated genes or insert new ones. Results appear this week in the early online edition of Proceedings of the National Academy of Sciences.
Earlier this year, UC San Diego biologists Ethan Bier and Valentino Gantz working with fruit flies announced the development of a new method for generating mutations in both copies of a gene. This mutagenic chain reaction involved using the Crispr-associated Cas9 nuclease enzyme and allowed for transmission of mutations through the germ line with an inheritance rate of 95 percent.
To ensure that the element carrying the malaria-blocking antibodies had reached the desired DNA site, the researchers included in the cassette a protein that gave the progeny red fluorescence in the eyes. Almost 100 percent of offspring -- 99.5 percent, to be exact -- exhibited this trait, which James said is an amazing result for such a system that can change inheritable traits.
The implications here are staggering. We are learning to edit genetic material and have the new edition persist into subsequent generations. It will only be a matter of time before the self-appointed seers among us start to improve the species according to their vision.
What could be more reasonable?
And from a previous blog:
This is a paragraph from the Boston Globe on the anxieties over a new gene editing technology, CRISPR-Cas9:
The study underlines the growing utility of the Crisper method, a powerful gene editing tool that allows access to a cell's nucleus to snip DNA to either replace mutated genes or insert new ones. Results appear this week in the early online edition of Proceedings of the National Academy of Sciences.
Earlier this year, UC San Diego biologists Ethan Bier and Valentino Gantz working with fruit flies announced the development of a new method for generating mutations in both copies of a gene. This mutagenic chain reaction involved using the Crispr-associated Cas9 nuclease enzyme and allowed for transmission of mutations through the germ line with an inheritance rate of 95 percent.
To ensure that the element carrying the malaria-blocking antibodies had reached the desired DNA site, the researchers included in the cassette a protein that gave the progeny red fluorescence in the eyes. Almost 100 percent of offspring -- 99.5 percent, to be exact -- exhibited this trait, which James said is an amazing result for such a system that can change inheritable traits.
The implications here are staggering. We are learning to edit genetic material and have the new edition persist into subsequent generations. It will only be a matter of time before the self-appointed seers among us start to improve the species according to their vision.
What could be more reasonable?
And from a previous blog:
This is a paragraph from the Boston Globe on the anxieties over a new gene editing technology, CRISPR-Cas9:
"A truly ethical bioethics should not bog down research in red tape, moratoria, or threats of prosecution based on nebulous but sweeping principles such as “dignity,” “sacredness,” or “social justice.” Nor should it thwart research that has likely benefits now or in the near future by sowing panic about speculative harms in the distant future. These include perverse analogies with nuclear weapons and Nazi atrocities, science-fiction dystopias like “Brave New World’’ and “Gattaca,’’ and freak-show scenarios like armies of cloned Hitlers, people selling their eyeballs on eBay, or warehouses of zombies to supply people with spare organs. Of course, individuals must be protected from identifiable harm, but we already have ample safeguards for the safety and informed consent of patients and research subjects."
This wonderful open-mindedness should be applauded--with a caveat. The experienced researchers in this field of CRISPR-Cas9 is the Chinese Huang group. Their recent paper showed the lack of specificity of the CRISPR-Cas9 with unexpected and wide ranging deletions in the genome. Worse, Huang says that the paper was rejected by Nature and Science, in part because of ethical objections; both journals declined to comment on the claim. But Huang did say this: “If you want to do it in normal embryos, you need to be close to 100%. That’s why we stopped. We still think it’s too immature.”
Which is to say, they were afraid.
No comments:
Post a Comment